Company news
Argent Biopharma Ltd news in 2022
Argent Biopharma Ltd's news releases, calls and decks from 2022, newest first.
$800,000 of funding received through Mercer Facility
December 23, 2022
Completion of CimetrA Efficacy Pre-clinical Trial
December 7, 2022
US$1,000,000 ArtemiC order delivered to US partner, AMC
December 4, 2022
Publication of Peer Reviewed Glioblastoma Research
December 2, 2022
Long COVID study Results
October 24, 2022
Pause in Trading
October 23, 2022
Operations Update
October 19, 2022
Appointment of UK Corporate Advisor and Company Update
October 4, 2022
TGA advertising Infringement Notice
September 28, 2022
US$550,000 Convertible Note Facility Funding
September 22, 2022
Interim Results - CimetrA Dosing Finding Study
September 20, 2022
US$750,000 Convertible Note Facility Funding
August 24, 2022
AMC Holdings Inc places US$1 million ArtemiC order
August 17, 2022
Study Results - Effects of CannEpil on driving performance
August 15, 2022
US$1.2M Tranche 1 Funding Recevied from Mercer
August 3, 2022
US$10M Financing Agreement signed with US Financier/Investor
July 29, 2022
Strategic Acquisition of 40% interest in ZAM Software Ltd
July 28, 2022
Amended June Quarterly Reports (amended App. 4C)
July 24, 2022
June Quarter Activities and Cash Flow Report
July 24, 2022
Long COVID Study Results for ArtemiC Support
July 14, 2022
Approvals received for South African CimetrA Clinical Trial
July 8, 2022
CimetrA anti-inflammatory pre-clinical study results
June 27, 2022
Glioblastoma pre-clinical trial results
June 16, 2022
Cognicann Clinical Trial Results
June 6, 2022
Response to ASX Aware Query
May 17, 2022
Patent Granted for CannEpiL SNEDDS
May 10, 2022
March 2022 Quarterly Activity and Cash Flow Reports
April 29, 2022
Patent Granted for CimetrA
April 21, 2022
Sciensus Rare EU & UK Sales and Distribution Agreement
April 5, 2022
Response to ASX Query
January 12, 2022
ArtemiC receives Indian importation and sales approval
January 6, 2022